Literature DB >> 16092153

Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Cardiac enzyme elevation after successful percutaneous coronary intervention is not an independent predictor of adverse outcomes.

Donald E Cutlip1, Richard E Kuntz.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16092153

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  10 in total

1.  Incidence of periprocedural myocardial infarction and cardiac biomarker testing after percutaneous coronary intervention in Japan: results from a multicenter registry.

Authors:  Takahide Arai; Shinsuke Yuasa; Hiroaki Miyata; Akio Kawamura; Yuichiro Maekawa; Shiro Ishikawa; Shigetaka Noma; Soushin Inoue; Yuji Sato; Shun Kohsaka; Keiichi Fukuda
Journal:  Heart Vessels       Date:  2012-12-29       Impact factor: 2.037

2.  Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial.

Authors:  Stefanie Schulz; Julinda Mehilli; Gjin Ndrepepa; Franz Dotzer; Michael Dommasch; Sebastian Kufner; Kathrin A Birkmeier; Klaus Tiroch; Robert A Byrne; Albert Schömig; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2011-03-08       Impact factor: 5.460

3.  Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI).

Authors:  Issam D Moussa; Lloyd W Klein; Binita Shah; Roxana Mehran; Michael J Mack; Emmanouil S Brilakis; John P Reilly; Gilbert Zoghbi; Elizabeth Holper; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2013-10-22       Impact factor: 24.094

4.  A randomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention.

Authors:  Byeong-Keuk Kim; Seung Jin Oh; Se-Jung Yoon; Dong Woon Jeon; Young-Guk Ko; Joo Young Yang
Journal:  Yonsei Med J       Date:  2011-09       Impact factor: 2.759

5.  Diagnostic and prognostic value of minor elevated cardiac troponin levels for percutaneous coronary intervention-related myocardial injury: a prospective, single-center and double-blind study.

Authors:  Min Zhang; Huiwei He; Ze-Mu Wang; Zhihui Xu; Ningtian Zhou; Zhengxian Tao; Bo Chen; Chunjian Li; Tiebing Zhu; Di Yang; Liansheng Wang; Zhijian Yang
Journal:  J Biomed Res       Date:  2014-02-10

6.  Relationship between Pre-Procedural Serum Lipid Profile and Post-Procedural Myocardial Injury in Patients Undergoing Elective Percutaneous Coronary Intervention.

Authors:  Mohsen Maadani; Seifollah Abdi; Sepideh Parchami-Ghazaee; Keivan Alizadeh; Hosein Fathi; Reza Musavi
Journal:  Res Cardiovasc Med       Date:  2013-10-28

7.  Diagnostic Accuracy of Post Procedural Creatine Kinase, MB Form can Predict Long-Term Outcomes in Patients Undergoing Selective Percutaneous Coronary Intervention?

Authors:  Mohsen Maadani; Sepideh Parchami-Ghazaee; Ghodratollah Barati; Monireh Soltani; Elahe Amiri; Behshid Ghadrdoost; Mona Heidarali
Journal:  Res Cardiovasc Med       Date:  2014-02-24

8.  A Comparison of Peri-Procedural Myocardial Infarction between Paclitaxel-Coated Balloon and Drug-Eluting Stent on De Novo Coronary Lesions.

Authors:  Ae Young Her; Kyoung Im Cho; Gillian Balbir Singh; Scot Garg; Yong Hoon Kim; Bon Kwon Koo; Eun Seok Shin
Journal:  Yonsei Med J       Date:  2017-01       Impact factor: 2.759

9.  Predictive Value of Aortic Valve Calcification for Periprocedural Myocardial Injury in Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Yohei Shibata; Hideki Ishii; Susumu Suzuki; Akihito Tanaka; Yosuke Tatami; Shingo Harata; Tomoyuki Ota; Yusaku Shimbo; Yohei Takayama; Ayako Kunimura; Kenshi Hirayama; Kazuhiro Harada; Naohiro Osugi; Toyoaki Murohara
Journal:  J Atheroscler Thromb       Date:  2016-10-13       Impact factor: 4.928

10.  Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition).

Authors:  Matthew A Cavender; Deepak L Bhatt; Gregg W Stone; Harvey D White; Ph Gabriel Steg; C Michael Gibson; Christian W Hamm; Matthew J Price; Sergio Leonardi; Jayne Prats; Efthymios N Deliargyris; Kenneth W Mahaffey; Robert A Harrington
Journal:  Circulation       Date:  2016-08-01       Impact factor: 29.690
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.